Floatz Rating
D31/100
Confidence
Indicative
Sponsor
Gilead Sciences
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
22High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03135028CT.gov Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults | — | Terminated | — | — | — |
NCT03013998CT.gov Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT02343939CT.gov Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Entospletinib (this asset) | Gilead Sciences | P1/2 | D · 31 |
| Gemtuzumab | M.D. Anderson Cancer Center | P4 | BBB |
| Posaconazole | AstraZeneca | P4 | BBB |
| (+)-Vincristine | Janssen Research & Development, LLC | P3 | BBB |
| Aclacinomycin | Chinese PLA General Hospital | P4 | BB |
| Idarubicin | Institute of Hematology & Blood Diseases Hospital, China | P4 | BB |
| Daunomycin | Shen yang | P4 | BB |
| Amsacrine | University Hospital, Toulouse | P4 | BB |
| Etoposide | Memorial Sloan Kettering Cancer Center | P4 | BB |
+42 more in the Acute Myeloid Leukemia cohort
Other indications for Entospletinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P2 | CC · 41 |
| Acute Myeloid Leukemia With Mutated NPM1 | — | P3 | CC · 40 |
| Mantle Cell Lymphoma | — | P2 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Entospletinib in Acute Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/entospletinib-acute-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →